Overview
Radioactive molecules can also be used to treat tumors or as a way to help control their growth and spread, as they are very small. Unlike radiotherapy in which the patient has to be exposed to radiation to get it, targeted radiotherapy uses a radioisotope to eliminate cancer cells and to prevent them from growing back.
The global radiopharmaceuticals in nuclear medicine market is estimated to be valued at US$ 6,700.5 million in 2020 and is expected to exhibit a CAGR of 8.0% over the forecast period (2020-2027).
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/70
Global Radiopharmaceuticals in Nuclear Medicine Market: Drivers
Approval and launch of new products is expected to propel growth of the global radiopharmaceuticals in nuclear medicine market over the forecast period. For instance, in 2018, Fresenius Kabi launched Adenosine Injection, USP in 60mg/20mL and 90mg/30mL dosage strengths, as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
Global Radiopharmaceuticals in Nuclear Medicine Market: Restraints
High cost of development of radiopharmaceuticals is expected to hinder growth of the global radiopharmaceuticals in nuclear medicine market. For instance, the cost of developing a drug for diagnostic imaging to commercialization is in the range of US$ 100 to US$ 200 million, according to the National Center for Biotechnology Information studies.
Recent Developments
Major players operating in the global radiopharmaceuticals in nuclear medicine market are focused on adopting partnership strategies to expand their product portfolio. For instance, in February 2018, Advanced Accelerator Applications S.A. partnered with Cancer Targeted Technology, LLC for R&D of an investigational new drug product, F-18-labeled CTT1057.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/70
Global Radiopharmaceuticals in Nuclear Medicine Market: Key Developments
Major players operating in the global radiopharmaceuticals in nuclear medicine market are focused on adopting merger and acquisition strategies to expand their product portfolio. For instance, in August 2018, Alliance Medical Group (a division of Life Healthcare Group) acquired Piramal Imaging and renamed it as Life Molecular Imaging, making it a part of the Alliance Medical Molecular Imaging division.
Global Radiopharmaceuticals in Nuclear Medicine Market: Competitive Landscape
Major players operating in the global radiopharmaceuticals in nuclear medicine market include, Advanced Accelerator Applications, S.A., Bracco S.p.A., Bayer AG, Curium Pharma, Cardinal Health, Inc., DuChemBio, Inc., Eli Lilly and Company, FUJIFILM Toyama Chemical Co., Ltd., General Electric Company, Jubilant Life Sciences Ltd., Life Molecular Imaging, Lantheus Holdings, Inc., Nihon Medi-Physics. Co. Ltd., NorthStar Medical Radioisotopes LLC, Progenics Pharmaceuticals, Inc., and Samyoung Unitech.
Buy This Report And Get Quick Access – https://www.coherentmarketinsights.com/insight/buy-now/70
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Radiopharmaceuticals in Nuclear Medicine Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Radiopharmaceuticals in Nuclear Medicine Industry Impact
Chapter 2 Global Radiopharmaceuticals in Nuclear Medicine Competition by Types, Applications, and Top Regions and Countries
2.1 Global Radiopharmaceuticals in Nuclear Medicine (Volume and Value) by Type
2.3 Global Radiopharmaceuticals in Nuclear Medicine (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Radiopharmaceuticals in Nuclear Medicine Market Analysis
Chapter 6 East Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis
Chapter 7 Europe Radiopharmaceuticals in Nuclear Medicine Market Analysis
Chapter 8 South Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis
Chapter 9 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis
Chapter 10 Middle East Radiopharmaceuticals in Nuclear Medicine Market Analysis
Chapter 11 Africa Radiopharmaceuticals in Nuclear Medicine Market Analysis
Chapter 12 Oceania Radiopharmaceuticals in Nuclear Medicine Market Analysis
Chapter 13 South America Radiopharmaceuticals in Nuclear Medicine Market Analysis
Chapter 14 Company Profiles and Key Figures in Radiopharmaceuticals in Nuclear Medicine Business
Chapter 15 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology
Continued….
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837